Prevalence of Pre-Treatment Sarcopenia in Patients Newly Diagnosed with Lymphoma

Charlotte Nørregaard Grønset; Mary Jarden; Jan Christensen; Martin Hutchings; Anders Tolver; Charlotte Suetta

doi:10.1159/000545358

Prevalence of Pre-Treatment Sarcopenia in Patients Newly Diagnosed with Lymphoma

Charlotte Nørregaard Grønset, Mary Jarden, Jan Christensen, Martin Hutchings, Anders Tolver, Charlotte Suetta

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

INTRODUCTION: Sarcopenia, defined by reduced muscle strength, mass, and performance, presents a significant challenge in cancer care due to its impact on treatment outcomes, quality of life, and survival. This study aimed to assess its prevalence in newly diagnosed lymphoma patients.

METHODS: Adults planned for first-line anthracycline-based chemotherapy were enrolled and screened for sarcopenia before treatment. Sarcopenia was defined by the European guidelines (EWGSOP2) using low muscle strength (hand-grip), low muscle mass (DXA), and low physical performance (gait speed).

RESULTS: Sixty-nine patients (mean age 57, 19 women) were included. Six patients (9%) had low hand-grip strength, 15 (22%) had low muscle mass, and 4 (6%) demonstrated low gait speed. Two patients met the criteria for sarcopenia, with one having severe sarcopenia.

CONCLUSION: Sarcopenia prevalence was 3%, but 22% had low muscle mass, suggesting muscle strength alone may not be an optimal screening tool for lymphoma patients.

Original language	English
Journal	Acta Haematologica
ISSN	0001-5792
DOIs	https://doi.org/10.1159/000545358
Publication status	E-pub ahead of print - 2025

Bibliographical note

Access to Document

10.1159/000545358

Cite this

@article{64fd885d7baf4776af0fa0937ab5018e,

title = "Prevalence of Pre-Treatment Sarcopenia in Patients Newly Diagnosed with Lymphoma",

abstract = "INTRODUCTION: Sarcopenia, defined by reduced muscle strength, mass, and performance, presents a significant challenge in cancer care due to its impact on treatment outcomes, quality of life, and survival. This study aimed to assess its prevalence in newly diagnosed lymphoma patients.METHODS: Adults planned for first-line anthracycline-based chemotherapy were enrolled and screened for sarcopenia before treatment. Sarcopenia was defined by the European guidelines (EWGSOP2) using low muscle strength (hand-grip), low muscle mass (DXA), and low physical performance (gait speed).RESULTS: Sixty-nine patients (mean age 57, 19 women) were included. Six patients (9%) had low hand-grip strength, 15 (22%) had low muscle mass, and 4 (6%) demonstrated low gait speed. Two patients met the criteria for sarcopenia, with one having severe sarcopenia.CONCLUSION: Sarcopenia prevalence was 3%, but 22% had low muscle mass, suggesting muscle strength alone may not be an optimal screening tool for lymphoma patients.",

author = "Gr{\o}nset, {Charlotte N{\o}rregaard} and Mary Jarden and Jan Christensen and Martin Hutchings and Anders Tolver and Charlotte Suetta",

note = "{\textcopyright} 2025 S. Karger AG, Basel.",

year = "2025",

doi = "10.1159/000545358",

language = "English",

journal = "Acta Haematologica",

issn = "0001-5792",

publisher = "S Karger AG",

}

TY - JOUR

T1 - Prevalence of Pre-Treatment Sarcopenia in Patients Newly Diagnosed with Lymphoma

AU - Grønset, Charlotte Nørregaard

AU - Jarden, Mary

AU - Christensen, Jan

AU - Hutchings, Martin

AU - Tolver, Anders

AU - Suetta, Charlotte

PY - 2025

Y1 - 2025

N2 - INTRODUCTION: Sarcopenia, defined by reduced muscle strength, mass, and performance, presents a significant challenge in cancer care due to its impact on treatment outcomes, quality of life, and survival. This study aimed to assess its prevalence in newly diagnosed lymphoma patients.METHODS: Adults planned for first-line anthracycline-based chemotherapy were enrolled and screened for sarcopenia before treatment. Sarcopenia was defined by the European guidelines (EWGSOP2) using low muscle strength (hand-grip), low muscle mass (DXA), and low physical performance (gait speed).RESULTS: Sixty-nine patients (mean age 57, 19 women) were included. Six patients (9%) had low hand-grip strength, 15 (22%) had low muscle mass, and 4 (6%) demonstrated low gait speed. Two patients met the criteria for sarcopenia, with one having severe sarcopenia.CONCLUSION: Sarcopenia prevalence was 3%, but 22% had low muscle mass, suggesting muscle strength alone may not be an optimal screening tool for lymphoma patients.

AB - INTRODUCTION: Sarcopenia, defined by reduced muscle strength, mass, and performance, presents a significant challenge in cancer care due to its impact on treatment outcomes, quality of life, and survival. This study aimed to assess its prevalence in newly diagnosed lymphoma patients.METHODS: Adults planned for first-line anthracycline-based chemotherapy were enrolled and screened for sarcopenia before treatment. Sarcopenia was defined by the European guidelines (EWGSOP2) using low muscle strength (hand-grip), low muscle mass (DXA), and low physical performance (gait speed).RESULTS: Sixty-nine patients (mean age 57, 19 women) were included. Six patients (9%) had low hand-grip strength, 15 (22%) had low muscle mass, and 4 (6%) demonstrated low gait speed. Two patients met the criteria for sarcopenia, with one having severe sarcopenia.CONCLUSION: Sarcopenia prevalence was 3%, but 22% had low muscle mass, suggesting muscle strength alone may not be an optimal screening tool for lymphoma patients.

U2 - 10.1159/000545358

DO - 10.1159/000545358

M3 - Journal article

C2 - 40188813

SN - 0001-5792

JO - Acta Haematologica

JF - Acta Haematologica

ER -